Any identifying information collected within will be
only for the purpose of expressing your concerns to your elected
officials in printed format.
showing support for
Patients Against Lymphomas'
Letter to CMS of 9/11/2007
RE: CMS-1392-FC, Reimbursement for
Radioimmunotherpies (Bexxar and Zevalin) ...
Against Lymphomas' Letter to CMS
Dear Honorable Members of Congress and
am writing to show my support for the letter* by Patients Against Lymphoma
to CMS and Senators on the Finance Committee, regarding the
ruling by CMS that will deny or limit access to
radioimmunotherapies (RIT), invaluable1 therapies
Letter to CMS, dated 9/11/2007: http://www.lymphomation.org/CMS-RIT.pdf
at stake: 1 Dr. Richard Wahl, Professor of Radiology and Oncology and Director of Nuclear Medicine and PET, Johns Hopkins University School of Medicine, and many other experts agree.
In a letter to HHS Secretary Mike Leavitt, Dr. Wahl states,
“Response rates of up to 95% have been reported and exciting new data are emerging from large trials again showing these drugs to be the most active single agents in lymphoma, working even when chemotherapy does not.
… Patients may actually be cured with these agents.
… Bexxar and Zevalin were developed in part with NIH / NCI support. It is very hard to decipher the logic by which the true fruits of the NIH, science translated to practice, are not made available to the public by its sibling in the HHS family, CMS. This suggests a dysfunctional HHS family, which I am sure is neither a desired perception nor result.”.
Please amend the CMS ruling to restore reimbursement rates for
Bexxar and Zevalin to 2007 rates during 2008.
This will allow CMS the time it needs to collect the
necessary data to base reimbursement rates for 2009 on
accurate data and appropriate classifications. We and the
patients who need these drugs, now and in the future, urge you
to act swiftly, before the ruling takes effect on January 1,
Time is running short, and so we beg you to act swiftly to save these